INSIGHTS ON DRUG DISCOVERY

Optimizing Lentiviral Producer Cell Line Yield
Producer cell lines boost lentiviral manufacturing efficiency via high-density culture, multiple harvests, and additive optimization for scalable production.
Patient-Centric Formulations In Pediatric Adherence
Improving pediatric adherence requires age-appropriate formulations, taste-masking, and swallowability strategies. Regulatory, clinical, and technological insights help overcome barriers and support safer, more effective therapies for children across developmental stages.
Scientific Poster: Driving High-Titer Productivity And Faster Timelines
Accelerated cell line development delivers high-titer biologics in weeks, supporting diverse modalities with robust analytics, scalable productivity, and proven stability across 60+ generations.
Top 5 Cell Line Development Challenges (And How To Avoid Them)
The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

Optimize Your CLD With Innovative And Flexible Transposase Technology
11/6/2025

To ensure speed and stability in the manufacture of your complex biologic — mAbs, antibodies, fusion proteins, and/or antibody drug conjugates — prioritize a high-performance CLD workflow.
Achieve Speed, Stability, And Compliance In Cell Line Development
11/6/2025

Partnering with a CDMO that demonstrates innovative and commercially validated cell line development capabilities is essential to protecting your market position and securing investor support.
Smart Input Selection And Process Refinement For iPBMCs
11/5/2025

Improved iPBMC manufacturing boosts TIL therapy reliability, safety, and affordability through donor screening, process refinements, and performance-based cell selection.
Top 8 Considerations For Choosing A PDX Model
10/7/2025

To guide your decision-making, we’ve outlined the top 10 criteria to consider when evaluating PDX models for your next oncology research or drug development program.
Second Sourcing Is Natural ... Your Current CDMO Should Understand
9/23/2025

Seasoned supply chain professionals say it is only natural to de-risk supply chains with sourcing materials and products at more than one external manufacturer ... no matter the insistence from the first external partner.

DRUG DISCOVERY SOLUTIONS

Transient Expression Platform: discoCHO

Learn how this transient platform accelerates biologics production, seamlessly transitioning from discovery to stable CHO-K1, ensuring scalability, and reducing risks in manufacturing therapeutic biologics.
CHEF1™ Expression Technology

The platform accelerates development of cell lines for cGMP production by using robust procedures and reliable raw materials, including chemically defined media, adapted Chinese hamster ovary (CHO) cells, and proprietary expression plasmids, to rapidly produce high levels of recombinant protein.
Discover A Platform For Antibodies With Increased ADCC Activity

Explore a platform for antibodies with increased ADCC activity that's compatible with various host cell lines, works across multiple vector configurations, and reduces core fucose within any cell line.
LV Edge System

By transitioning from a 4-plasmid transient system to 1- or 0-plasmid configurations, the LV Edge systems reduce or eliminate the need for GMP plasmids, lowering costs and supply chain risks.
SUREtechnology Platform™

Explore how an advanced Cell Line Development (CLD) platform for new biologics can enable CHO-based cell line development; ensure premium, stable, and high-yield results; overcome common expression bottlenecks; and provide robust verification, genomic characterization, and monoclonality assessment services.